APA
Willis M., Pearson O., Illes Z., Sejbaek T., Nielsen C., Duddy M., Petheram K., van Munster C., Killestein J., Malmeström C., Tallantyre E. & Robertson N. (2017). An observational study of alemtuzumab following fingolimod for multiple sclerosis. : Neurology(R) neuroimmunology & neuroinflammation.
Chicago
Willis Mark, Pearson Owen, Illes Zsolt, Sejbaek Tobias, Nielsen Christian, Duddy Martin, Petheram Kate, van Munster Caspar, Killestein Joep, Malmeström Clas, Tallantyre Emma and Robertson Neil. 2017. An observational study of alemtuzumab following fingolimod for multiple sclerosis. : Neurology(R) neuroimmunology & neuroinflammation.
Harvard
Willis M., Pearson O., Illes Z., Sejbaek T., Nielsen C., Duddy M., Petheram K., van Munster C., Killestein J., Malmeström C., Tallantyre E. and Robertson N. (2017). An observational study of alemtuzumab following fingolimod for multiple sclerosis. : Neurology(R) neuroimmunology & neuroinflammation.
MLA
Willis Mark, Pearson Owen, Illes Zsolt, Sejbaek Tobias, Nielsen Christian, Duddy Martin, Petheram Kate, van Munster Caspar, Killestein Joep, Malmeström Clas, Tallantyre Emma and Robertson Neil. An observational study of alemtuzumab following fingolimod for multiple sclerosis. : Neurology(R) neuroimmunology & neuroinflammation. 2017.